Evidence map›Paper›PMID 31095703›Full record

ReviewInflammatory bowel diseases2019

Challenges in IBD Research: Novel Technologies.

Manish Dhyani, Nitin Joshi, Willem A Bemelman, Michael S Gee, Vijay Yajnik, André D'Hoore, Giovanni Traverso, Mark Donowitz, Gustavo Mostoslavsky, Timothy K Lu and 14 more

Abstract readReview
In one paragraph

Review in Inflammatory bowel diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Challenges in IBD Research 2024: Novel Technologies.Inflammatory bowel diseases · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Challenges in IBD Research: Environmental Triggers.Inflammatory bowel diseases · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Manish DhyaniLahey Hospital & Medical Center, Burlington, Massachusetts.
Nitin JoshiBrigham and Women's Hospital, Boston, Massachusetts.
Willem A BemelmanAcademic Medical Centre, Amsterdam, Netherlands.
Michael S GeeMassachusetts General Hospital, Boston, Massachusetts.
Vijay YajnikTakeda Pharmaceutical Company, Boston, Massachusetts.
André D'HooreUniversity Hospital Gasthuisberg and University of Leuven, Leuven, Belgium.
Giovanni TraversoBrigham and Women's Hospital, Harvard Medical School and Massachusetts Institute of Technology, Boston, Massachusetts.
Mark DonowitzJohns Hopkins University School of Medicine, Baltimore, Maryland.
Gustavo MostoslavskyBoston University School of Medicine, Boston, Massachusetts.
Timothy K LuMassachusetts Institute of Technology, Cambridge, Massachusetts.
Neil LineberryTakeda Pharmaceutical Company, Boston, Massachusetts.
Heiko G NiessenBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Dan PeerSchool of Molecular Cell Biology and Biotechnology, Tel Aviv University, Tel Aviv, Israel.
Jonathan BraunInflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai, Los Angeles, California.
Conor P DelaneyCleveland Clinic Foundation, Cleveland, Ohio.
Marla C DubinskyIcahn School of Medicine at Mount Sinai, New York, New York.
Ashley N GuilloryUniversity of Texas Medical Branch, Galveston, Texas.
Maria PereiraGecko Biomedical, Paris, France.
Nataly ShtraizentCrohn's & Colitis Foundation, New York, New York.
Gerard HonigCrohn's & Colitis Foundation, New York, New York.
David Brent PolkDepartment of Biochemistry and Molecular Biology, University of Southern California.
Andrés Hurtado-LorenzoCrohn's & Colitis Foundation, New York, New York.
Jeffrey M KarpDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology, Broad Institute and Harvard Stem Cell Institute, Boston, Massachusetts.
Fabrizio MichelassiNew York-Presbyterian Hospital and Weill Cornell School of Medicine, New York, New York.

Funding

STRUCTURE-FUNCTION RELATIONSHIPS IN THE ALIMENTARY TRACTP30DK034854 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WAYNE I LENCER · 1986 to 2026
$32.4M
CYTOKINE REGULATION OF INTESTINAL EPITHELIAL RESTITUTIONR01DK056008 · NIDDK · VANDERBILT UNIVERSITY · PI POLK, D BRENT · 1999 to 2020
$6.8M
Stem Cell Dynamics in Colonic Epithelial RepairR01DK108648 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Cambrian Yangshao Liu, D Brent Polk · 2016 to 2026
$2.7M
NIDDK NIH HHS P30 DK034854NIDDK NIH HHS R01 DK056008NIDDK NIH HHS R01 DK108648
6 · The paper itself

Abstract

Novel technologies is part of five focus areas of the Challenges in IBD research document, which also includes preclinical human IBD mechanisms, environmental triggers, precision medicine and pragmatic clinical research. The Challenges in IBD research document provides a comprehensive overview of current gaps in inflammatory bowel diseases (IBD) research and delivers actionable approaches to address them. It is the result of a multidisciplinary input from scientists, clinicians, patients, and funders, and represents a valuable resource for patient centric research prioritization. In particular, the novel technologies section is focused on prioritizing unmet clinical needs in IBD that will benefit from novel technologies applied to: 1) non-invasive detection and monitoring of active inflammation and assessment of treatment response; 2) mucosal targeted drug delivery systems; and 3) prevention of post-operative septic complications and treatment of fistulizing complications. Proposed approaches include development of multiparametric imaging modalities and biosensors, to enable non invasive or minimally invasive detection of pro-inflammatory signals to monitor disease activity and treatment responses. Additionally, technologies for local drug delivery to control unremitting disease and increase treatment efficacy while decreasing systemic exposure are also proposed. Finally, research on biopolymers and other sealant technologies to promote post-surgical healing; and devices to control anastomotic leakage and prevent post-surgical complications and recurrences are also needed.

Indexed as

Diagnostic ImagingDigestive System Surgical ProceduresDrug Delivery SystemsGastrointestinal AgentsHumansImmunosuppressive AgentsInflammatory Bowel DiseasesGastrointestinal AgentsImmunosuppressive AgentsanastomosisCrohn’s diseasedrug deliveryfistulanon-invasive imagingradiologysepsissurgeryulcerative colitis

Identifiers

PMID31095703
PMCPMC6787667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.